오버행 리스크 제로! 빚 없는 바이오 기업, 온코닉테라퓨틱스 지배구조 전격 검증

Many investors share a common distrust regarding biotech companies. The skepticism stems from the question, "They just spend money under the torturous false hope of new drug development; when will they actually generate profits?" As cases of "money-eating hippos" collapsing due to clinical trial failures and financial difficulties repeated themselves despite pouring trillions of won into research, the K-Bio sector faced cold indifference for a time. However, there is a company that has recently broken through these prejudices head-on and demonstrated a "qualitative change (Valuation Re-rating)." That company is Onconic Therapeutics, which listed on the KOSDAQ in December 2024. We have analyzed the strategies of this company—which succeeded in turning a profit in a short period immediately after listing and successfully launched Korea's 37th new drug in the market—through key insights from financial and biotech perspectives.